Plain-English translation of NCT06799520 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage research trial testing a new medication called , given as a subcutaneous injection (under the skin), in people with autoimmune diseases. The trial is checking whether the medication is safe to use and how well people tolerate it, while also studying how the medication works in the body. Researchers want to understand if this treatment could help people with lupus, alopecia areata, or immune-related kidney problems.
Autoimmune diseases occur when the immune system attacks the body's own cells, causing inflammation and tissue damage. Current treatments don't work well for everyone, and some people suffer serious side effects. This medication is designed to work in a new way to calm down the overactive immune system, and this trial will help determine if it's a safe option for patients who need better treatment choices.
If you qualify, you will receive injections of the medication under your skin at regular intervals over 21 weeks, while continuing your usual autoimmune disease treatment. You'll visit the research clinic multiple times for blood tests, physical exams, and check-ins to monitor how you're responding and whether you have any side effects. The entire study lasts about 9 to 12 months, including a follow-up period after you stop receiving the medication.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
Bulgaria
Moldova
Romania
Spain